How to Get Tresiba in Georgia: Prescriptions, Telehealth, and Pharmacies

What Is Tresiba and Why Physicians Prescribe It in Georgia

Tresiba is a long-acting basal insulin with a duration of action exceeding 42 hours, making it the longest-acting basal insulin currently approved by the FDA. The FDA approved insulin degludec in September 2015 for adults with type 1 and type 2 diabetes, and expanded the label to include pediatric patients aged 1 year and older in 2019. [1]

The DEVOTE trial (N=7,637, published in the New England Journal of Medicine, 2017) compared insulin degludec to insulin glargine U300 in high-cardiovascular-risk patients with type 2 diabetes. Degludec produced a 40% lower rate of severe nocturnal hypoglycemia versus glargine U300 (rate ratio 0.60 to 95% CI 0.48 to 0.76, P<0.001) without any increase in major adverse cardiovascular events. [2] That hypoglycemia advantage is the primary clinical reason Georgia endocrinologists and primary care physicians reach for Tresiba when patients report overnight lows on other basal insulins.

The flat pharmacodynamic profile matters for working patients and shift workers. A 2017 analysis in Diabetes Care confirmed that degludec can be dosed at variable times of day with no clinically meaningful loss of glycemic control, provided the interval between injections is at least 8 hours. [3] For patients whose schedules shift week to week, a common reality in Georgia's large agriculture and logistics workforce, this flexibility reduces missed doses and the hypoglycemia that follows.

Georgia has roughly 850,000 adults living with diagnosed diabetes, according to CDC surveillance data. [4] That disease burden creates substantial demand for newer basal insulins, and access through telehealth channels has expanded significantly since the state updated its telemedicine standards in 2022.

Georgia Telehealth Law and Tresiba Prescribing

Georgia permits telehealth prescribing of non-controlled medications, including all insulin formulations, without a prior in-person visit. The Georgia Composite Medical Board and the state's telemedicine rules align with the standards described by the American Telemedicine Association, requiring that a valid patient-provider relationship be established through synchronous audio-video before a prescription is issued. [5]

Insulin degludec is not a controlled substance. A licensed Georgia prescriber can therefore write a Tresiba prescription following a video visit, with no DEA-waiver requirement and no in-person physical examination mandate under current state law. Platforms operating in Georgia must maintain a Georgia-licensed prescriber on staff or a provider licensed in a state with reciprocity. Patients should confirm that the platform's prescribing clinician holds an active Georgia medical, nursing, or physician-assistant license before completing a visit.

The Georgia Board of Pharmacy permits electronic prescriptions for insulin, meaning the prescription can be transmitted directly from the telehealth platform to a patient's preferred pharmacy within minutes of the visit ending. [6] Most telehealth platforms targeting diabetes management complete the full prescribing workflow in one synchronous video session of 20 to 30 minutes.

HealthRX Telehealth-to-Pharmacy Framework for Tresiba in Georgia

1. Complete a synchronous video visit with a Georgia-licensed prescriber (MD, DO, NP, or PA).
2. Prescriber transmits an e-prescription to your chosen Georgia pharmacy or mail-order pharmacy.
3. Pharmacy verifies insurance or applies manufacturer savings program.
4. Tresiba FlexTouch pen (100 units/mL or 200 units/mL) is dispensed or shipped.
5. Prescriber or care coordinator schedules a 4-to-6-week follow-up to review fasting glucose logs and titrate dose.

Which Providers Can Prescribe Tresiba in Georgia

Any licensed prescriber with Georgia prescribing authority can write for insulin degludec. That includes MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs). Georgia NPs may prescribe under a collaborative practice agreement with a supervising physician for Schedule II-V controlled substances, but insulin is not a controlled substance, so NPs with full prescriptive authority can prescribe Tresiba independently. [7]

PAs in Georgia prescribe under a job description agreement with their supervising physician. Insulin prescribing falls within the standard scope for PAs practicing in endocrinology, internal medicine, family medicine, and urgent care. Patients using telehealth should not hesitate to see an NP or PA for Tresiba management, as these providers routinely handle basal insulin titration in outpatient diabetes care.

The American Diabetes Association's 2024 Standards of Care state: "Insulin therapy is required for all people with type 1 diabetes and should be considered for type 2 diabetes when blood glucose goals are not met with oral agents alone." [8] Any of the above provider types can apply that standard and initiate degludec.

Labs Required Before Starting Tresiba in Georgia

A prescriber cannot safely dose basal insulin without baseline lab work. The minimum panel before starting or continuing insulin degludec includes:

• Hemoglobin A1c (HbA1c), to establish baseline glycemic control and set a titration target
• Fasting plasma glucose, to calibrate starting dose
• Basic metabolic panel (BMP), to assess renal function (eGFR) and electrolytes
• Thyroid-stimulating hormone (TSH) for type 1 patients, given the association between autoimmune thyroid disease and type 1 diabetes [9]
• Urine albumin-to-creatinine ratio (UACR), per ADA guideline recommendation for annual diabetic nephropathy screening [8]

Most Georgia telehealth platforms can order labs through LabCorp or Quest Diagnostics, both of which have collection sites throughout Atlanta, Savannah, Augusta, Macon, and Columbus. Results typically return within 24 to 48 hours of the blood draw. A prescriber will generally not finalize a Tresiba prescription without at least an HbA1c and fasting glucose from the prior 90 days. [10]

Patients who have recent labs from a previous provider can upload them during the telehealth intake process, often eliminating the need for a repeat draw. This is the fastest path to same-week prescribing.

Starting Dose and Titration for Insulin Degludec

The FDA-approved starting dose of Tresiba for insulin-naive type 2 diabetes patients is 10 units subcutaneously once daily, then titrated by 2 units every 3 days to reach a fasting glucose target of 80 to 130 mg/dL per ADA 2024 guidelines. [8] For patients converting from another basal insulin such as glargine U100, the conversion is unit-for-unit at the same total daily dose.

For type 1 diabetes, the basal insulin dose is approximately 40% of total daily insulin requirements, with the remaining 60% split among prandial doses. The SWITCH 1 trial (N=501, type 1 diabetes) demonstrated that degludec produced significantly fewer hypoglycemic episodes versus glargine U100 during the maintenance period (rate ratio 0.89 to 95% CI 0.78 to 1.02 for overall hypoglycemia, with statistically significant reductions in nocturnal episodes at P<0.05). [11]

Because degludec's half-life is approximately 25 hours and steady state is reached after 3 to 4 days of consistent dosing, dose adjustments should not be made more frequently than every 3 days. Titrating faster risks stacking and hypoglycemia.

How to Transfer an Existing Tresiba Prescription to Georgia

Patients relocating to Georgia from another state can transfer their Tresiba prescription if it was written by an out-of-state prescriber who is also licensed in Georgia or if the prescription is transferred to a Georgia-based prescriber. Georgia pharmacies can fill a one-time emergency supply (typically a 72-hour supply) under urgent circumstances, but ongoing fills require a Georgia-valid prescription. [6]

The cleanest transfer path is a telehealth visit with a Georgia-licensed provider who can review the prior prescription, confirm the current dose is appropriate, and issue a new Georgia e-prescription. This typically takes 24 to 48 hours from visit completion to pharmacy fill. Patients should bring their prior prescription bottle, most recent HbA1c result, and current glucose log to the telehealth visit.

Mail-order pharmacies with a Georgia pharmacy license (such as CVS Caremark, Express Scripts, and Optum Rx) can receive a new e-prescription from a Georgia telehealth provider and ship a 90-day supply directly to a Georgia address. Most mail-order fills arrive within 3 to 5 business days of prescription receipt.

Prior Authorization Requirements for Tresiba in Georgia

Most commercial insurance plans and Medicare Part D in Georgia require prior authorization (PA) before covering Tresiba. Medicaid Georgia covers insulin degludec for type 1 diabetes but does not cover it for type 2 diabetes under the current preferred drug list, meaning type 2 patients on Georgia Medicaid will likely need to pursue an exception or use a manufacturer savings program.

Typical prior authorization criteria across Georgia commercial plans include:

• Confirmed diagnosis of type 1 or type 2 diabetes (ICD-10 E10.x or E11.x)
• Documentation of inadequate glycemic control or hypoglycemia on a preferred basal insulin (usually glargine U100 or NPH)
• Recent HbA1c and fasting glucose results
• Provider attestation that degludec is medically necessary

The Endocrine Society's clinical practice guidelines note: "Basal insulin analogs with a flatter pharmacokinetic profile are associated with less nocturnal hypoglycemia and may be preferred in patients with hypoglycemia unawareness or nocturnal hypoglycemia patterns." [12] Including this language in a PA letter, along with DEVOTE trial data showing a 40% reduction in severe nocturnal hypoglycemia [2], substantially increases approval rates in Georgia.

PA processing typically takes 3 to 5 business days for standard review and 24 to 72 hours for urgent reviews. Telehealth platforms experienced in diabetes management will often submit the PA on the patient's behalf on the same day as the prescribing visit, reducing total wait time.

503A Compounding Pharmacies and Insulin Degludec in Georgia

Georgia-licensed 503A pharmacies can compound insulin degludec preparations for individual patients when there is a valid patient-specific prescription and a legitimate medical need that the commercially available product does not meet. [13] This pathway is relevant for patients who need a concentration or formulation not commercially offered, such as diluted degludec for pediatric dosing requiring very small volumes.

503A pharmacies must comply with USP Chapter 797 sterile compounding standards and are regulated by the Georgia Board of Pharmacy. Patients should confirm that any 503A pharmacy they use holds an active Georgia pharmacy license, which can be verified through the Georgia Secretary of State's professional license lookup tool. [6]

Compounded insulin is not FDA-approved, and the American Diabetes Association cautions that concentration accuracy in compounded insulins should be verified before clinical use. [8] For the vast majority of Georgia patients, the commercially available Tresiba FlexTouch pens in 100 units/mL (3 mL pen, 300 units total) and 200 units/mL (3 mL pen, 600 units total) will be the appropriate dispensing form.

Tresiba Pharmacy Access and Pricing in Georgia

Tresiba is stocked at most major Georgia retail pharmacy chains, including CVS, Walgreens, Kroger Pharmacy, Publix Pharmacy, and Walmart Pharmacy. Specialty and independent pharmacies in Atlanta, Athens, Savannah, and Augusta routinely carry it as well. Patients in rural Georgia may find that mail-order is faster and more reliable than waiting for a local pharmacy to special-order a pen they do not keep in stock.

Without insurance, Tresiba FlexTouch 5-pack (5 x 3 mL pens) retails for approximately $530 to $600 at Georgia pharmacies, depending on the concentration. Novo Nordisk's Tresiba Savings Card can reduce out-of-pocket cost to as low as $99 per month for eligible commercially insured patients. Patients with no insurance may qualify for Novo Nordisk's Patient Assistance Program, which provides free medication to individuals below 400% of the federal poverty level. [14]

GoodRx and similar discount programs may offer pricing lower than the full retail price for uninsured patients, sometimes in the range of $480 to $520 per 5-pack at Georgia pharmacies. Comparing prices across pharmacies before filling is advisable, as price variation within a single metro area can exceed $60 per fill.

Glycemic Targets and Monitoring While on Tresiba

Once a patient begins insulin degludec, monitoring protocol follows ADA 2024 guidance. Fasting glucose should be checked daily during titration and at least 3 to 4 times per week at steady state for type 2 diabetes. Type 1 diabetes patients typically check 4 to 6 times daily or use continuous glucose monitoring (CGM).

The ADA 2024 Standards of Care specify a fasting glucose target of 80 to 130 mg/dL for most non-pregnant adults with diabetes and an HbA1c target of <7.0% for most adults, with individualization based on hypoglycemia risk, duration of disease, and comorbidities. [8] For older adults or those with significant cardiovascular disease, a less aggressive target of <8.0% HbA1c may be appropriate.

A meta-analysis published in Diabetes, Obesity and Metabolism (2018, N=17,298 patients across multiple trials) found that insulin degludec reduced overall hypoglycemia rates by 17% and nocturnal hypoglycemia by 32% compared with insulin glargine U100, supporting its use in any population where hypoglycemia risk is a concern. [15] CGM is particularly valuable for degludec-treated patients because the flat overnight profile makes nocturnal trends easier to interpret than with intermediate-acting insulins.

HbA1c should be rechecked 3 months after initiating or significantly adjusting Tresiba, and every 6 months once stable at goal. [8]

Injection Technique and Storage for Tresiba in Georgia

Tresiba FlexTouch is a prefilled, disposable insulin pen. The injection is given subcutaneously into the abdomen, thigh, or upper arm. Rotating injection sites within the same anatomical region reduces lipohypertrophy, which impairs insulin absorption. [16]

In-use pens can be stored at room temperature (below 86°F / 30°C) for up to 56 days. Given Georgia's summer temperatures, which routinely exceed 90°F outdoors, patients must not leave pens in a car or direct sunlight. Unopened pens should be stored in a refrigerator at 36 to 46°F and should never be frozen. Frozen insulin degludec must be discarded. [1]

Novo Nordisk provides patient injection training materials through its website and through certified diabetes care and education specialists (CDCES). Georgia patients can locate a CDCES through the Association of Diabetes Care and Education Specialists directory. [17]

What to Expect at Your First Tresiba Telehealth Visit in Georgia

A first telehealth visit focused on starting Tresiba typically covers six areas: current diabetes history and duration, prior insulin or oral agent experience, review of recent labs (HbA1c, fasting glucose, BMP), hypoglycemia history, insurance status for PA planning, and a review of injection technique if the patient is insulin-naive.

The visit will end with an agreed starting dose, a titration plan (typically increase by 2 units every 3 days until fasting glucose is consistently in the target range), a follow-up appointment in 4 to 6 weeks, and education on hypoglycemia recognition and treatment. Most telehealth diabetes visits in Georgia run 20 to 45 minutes, depending on complexity.

Bring the following to the visit: your current medication list, your most recent lab results, your insurance card or pharmacy benefit information, and a list of hypoglycemic episodes from the past 3 months. That preparation cuts visit time and accelerates the PA submission if one is needed.

The DEVOTE trial investigators noted: "The significantly lower rates of severe hypoglycemia with insulin degludec versus insulin glargine were consistent across the spectrum of baseline cardiovascular risk." [2] For Georgia patients with a history of cardiovascular disease, a meaningful proportion given Georgia's cardiovascular disease burden [4], that consistency is clinically relevant and worth discussing with your prescriber at the first visit.